Identification of miRNA-3652 Signature as a Promising Diagnostic Biomarker in FFPE Tissues of Breast Cancer Patients

Lina Abdulfatah Abdulrazaq; Hazha Jamal Hidayat

doi:10.21271/ZJPAS.37.6.2

Authors

Lina Abdulfatah Abdulrazaq Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq
Hazha Jamal Hidayat Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq

DOI:

https://doi.org/10.21271/ZJPAS.37.6.2

Keywords:

Breast Cancer, miR-3652, Biomarker

Abstract

Researchers have recently begun to investigate microRNAs (miRNAs) as a potential new class of biomarkers. In this study, we examine whether miR-3652 may be regarded as a powerful biomarker for predicting the prognosis of breast cancer (BC). In this study, the expression level of miR-3652 was detected in 30 FFPE tissue pairs of tumoral samples and their adjacent non-tumoral tissues using qRT-PCR. The clinicopathological characteristics of patients relative to miR-3652 expression level, along with fold change analysis employing the 2^-ΔΔCT method, were also investigated. All statistical analyses were conducted using GraphPad Prism version 8.4.3 (686). We found that the miR-3652 level in BC FFPE tissues is notably increased compared to matched non-cancerous specimens. Also, we analyzed the association between the expression level of miR-3652 and the clinicopathological parameters of BC patients. The overexpression of miR-3652 exhibited no significant association with age, tumor stage, ER status, PR status, TNM stage, or calcification. All HER2-negative status patients suggested a potential trend (P = 0.017), indicating that low miR-3652 expression was more common in HER2-negative status subjects. Moreover, the p-value, AUC, Std. Error, sensitivity, and specificity are (p < 0.018, 0.6772, 0.06905, 0.53, and 0.80, respectively), which signifies a moderate capacity of the test to differentiate between patients with tumors and controls. The results of fold change analysis employing the 2^-ΔΔCT method indicated a (6.89)-fold elevation in miR-3652 expression in tumors relative to controls. This suggests that miR-3652 may have an oncogenic role in carcinogenesis, potentially promoting BC development. In conclusion, our results demonstrated that elevated miR-3652 expression associates with the progression of BC, and this indicates that miR-3652 may possess an oncogenic function in tumorigenesis, possibly facilitating BC progression. Additional studies are required.

References

AFIFI, A. M., SAAD, A. M., AL‐HUSSEINI, M. J., ELMEHRATH, A. O., NORTHFELT, D. W. & SONBOL, M. B. 2020. Causes of death after breast cancer diagnosis: A US population‐based analysis. Cancer, 126, 1559-1567.

CEJALVO, J. M., PASCUAL, T., FERNÁNDEZ-MARTÍNEZ, A., BRASÓ-MARISTANY, F., GOMIS, R. R., PEROU, C. M., MUÑOZ, M. & PRAT, A. 2018. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer treatment reviews, 67, 63-70.

CSERNI, G. 2020. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica, 112, 25.

DVORKIN-GHEVA, A. & HASSELL, J. A. 2014. Identification of a novel luminal molecular subtype of breast cancer. PLoS One, 9, e103514.

FERNANDEZ-MOURE, J. S., VAN EPS, J., WEINER, B. K., FERRARI, M. & TASCIOTTI, E. 2014. MicroRNA and Drug Delivery. MicroRNA in Development and in the Progression of Cancer, 359-403.

HUSSEN, B. M., ABDULLAH, K. H., ABDULLAH, S. R., MAJEED, N. M., MOHAMADTAHR, S., RASUL, M. F., DONG, P., TAHERI, M. & SAMSAMI, M. 2023a. New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets. Non-coding RNA Research, 8, 645-660.

HUSSEN, B. M., RASUL, M. F., ABDULLAH, S. R., HIDAYAT, H. J., FARAJ, G. S. H., ALI, F. A., SALIHI, A., BANIAHMAD, A., GHAFOURI-FARD, S. & RAHMAN, M. 2023b. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Military Medical Research, 10, 32.

HUSSEN, B. M., SALEEM, S. J., ABDULLAH, S. R., MOHAMADTAHR, S., HIDAYAT, H. J., RASUL, M. F., TAHERI, M. & KIANI, A. 2023c. Current landscape of miRNAs and TGF‐β signaling in lung cancer progression and therapeutic targets. Molecular and Cellular Probes, 72, 101929.

JOHNSON, K. S., CONANT, E. F. & SOO, M. S. 2021. Molecular subtypes of breast cancer: a review for breast radiologists. Journal of Breast Imaging, 3, 12-24.

OTMANI, K. & LEWALLE, P. 2021. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Frontiers in oncology, 11, 708765.

PARK, M., KIM, D., KO, S., KIM, A., MO, K. & YOON, H. 2022. Breast cancer metastasis: mechanisms and therapeutic implications. International journal of molecular sciences, 23, 6806.

RUSSO, J. & RUSSO, J. 2021. Defining Breast Cancer. The Future of Prevention and Treatment of Breast Cancer, 1-31.

SATHIPATI, S. Y. & HO, S.-Y. 2021. Identification of the miRNA signature associated with survival in patients with ovarian cancer. Aging (Albany NY), 13, 12660.

SCHRATT, G. 2009. Fine-tuning neural gene expression with microRNAs. Current opinion in neurobiology, 19, 213-219.

SUMAIRA, S., VIJAYARATHNA, S., HEMAGIRRI, M., ADNAN, M., HASSAN, M. I., PATEL, M., GUPTA, R., CHEN, Y., GOPINATH, S. C. & KANWAR, J. R. 2024. Plant bioactive compounds driven microRNAs (miRNAs): a potential source and novel strategy targeting gene and cancer therapeutics. Non-coding RNA Research.

SVORONOS, A. A., ENGELMAN, D. M. & SLACK, F. J. 2016. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer research, 76, 3666-3670.

TOMASELLO, L., DISTEFANO, R., NIGITA, G. & CROCE, C. M. 2021. The MicroRNA family gets wider: the IsomiRs classification and role. Frontiers in cell and developmental biology, 9, 668648.

WILKINSON, L. & GATHANI, T. 2022. Understanding breast cancer as a global health concern. The British journal of radiology, 95, 20211033.

ZHANG, J., ABRAMS, Z., PARVIN, J. D. & HUANG, K. 2016. Integrative analysis of somatic mutations and transcriptomic data to functionally stratify breast cancer patients. BMC genomics, 17, 183-193.